NEW YORK (GenomeWeb News) – Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma plan to develop and market a diagnostic tool to rapidly diagnose patients who have lipoprotein lipase deficiency (LPLD) and may be candidates for an AMT therapeutic.

AMT said today that it will collaborate with Progenika to develop the LPLchip, which is based on Progenika's DNA-chip technology, to diagnose patients with complete and partial LPLD who may benefit from treatment with AMT's Glybera, a gene therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.